Accuray, Inc. (NASDAQ:ARAY)

CAPS Rating: 4 out of 5

The Company has developed the commercially available intelligent robotic radiosurgery system, the CyberKnife system, designed to treat solid tumors anywhere in the body as an alternative to traditional surgery.

Results 1 - 20 of 109 : 1 2 3 4 5 6 Next »

Recs

0
Member Avatar DTCook (22.65) Submitted: 3/17/2014 10:23:31 AM : Outperform Start Price: $9.81 ARAY Score: -37.33

CyberKnife gaining market share in radiosurgery, captured 10-12% of the ultra focused radiation market thus far. On the verge of profitability, after burning cash for years to build business. Strong financial position w/ $170M cash and investments ($780M mkt cap).

Recs

0
Member Avatar dstoeckel (< 20) Submitted: 3/6/2014 7:34:19 PM : Outperform Start Price: $9.64 ARAY Score: -34.64

Will pick up some people who are on the fence regarding ISRG

Recs

0
Member Avatar s2dbaker (79.48) Submitted: 9/10/2013 6:39:04 AM : Outperform Start Price: $6.49 ARAY Score: -11.46

This pick is counter-intuitive. I don't like this stock, I think this company is going nowhere. Accuray has shown an amazing ability to fail to produce a profit. However, ARAY keeps showing up in my stock screens and like the lyric that Liza Minnelli sings in Cabaret, "maybe THIS time I'll win".

Recs

0
Member Avatar WilliamCrook2003 (70.57) Submitted: 8/6/2013 3:23:36 PM : Outperform Start Price: $6.22 ARAY Score: -5.80

Undervalued.

Recs

0
Member Avatar robertshrestha (58.20) Submitted: 12/26/2011 11:13:27 PM : Outperform Start Price: $4.38 ARAY Score: +0.80

Nice growth prospects as uses for CyberKnife system expands, solid balance sheet, beaten-down stock price. What's not to like?!

Recs

0
Member Avatar NJ7 (36.34) Submitted: 12/21/2011 10:17:49 PM : Outperform Start Price: $4.47 ARAY Score: -4.54

Accuray's niche is robotic laser surgery. This has low toxicity and a dramatic impact on cancer treatment (though no treatment is perfect). ARAY is both first mover and top dog in this particular area because I believe its CyberKnife to be the best available technology as reflected by widespread adaptation. Its acquisition of TomoTherapy allowed it to expand into related fields. Varian Medical is the main competitor with differing products providing similar methods of treatment. But the essential premise I base my investment thesis on is that hospitals are not nearly saturated with either technology. There are hundreds of hospitals with these technologies, eventually there could be thousands in the USA alone. If the CyberKnife can consolidate its position and/or displace Varian Medical, the sky is the limit. But if Varian Medical starts to take market share as saturation approaches, the outcome is less rosy.

Recs

0
Member Avatar MarketHustler (< 20) Submitted: 8/22/2011 8:45:00 PM : Outperform Start Price: $4.53 ARAY Score: -23.50

Buying at a discount and there is really nothing to show why they are so undervalued except for S&P downgrade scare. Waiting for some consolidation

Recs

0
Member Avatar ayaghsizian (95.28) Submitted: 5/6/2011 3:59:04 PM : Outperform Start Price: $7.98 ARAY Score: -63.66

my name

Recs

0
Member Avatar hildis (37.75) Submitted: 3/4/2011 2:53:26 AM : Underperform Start Price: $10.05 ARAY Score: +83.23

There are other, more important factors than 3D beam positioning when treating a cancer patient. The Accuray system has quite a low output and is limited to one energy. This means that treatment times are MUCH longer (up to 10x). This means that the patient throughput is much lower than with a Varian accelerator = loss of income. It also means that the patient has to lie on the table for a much longer time and that is VERY uncomfortable even for a healthy person!

Recs

0
Member Avatar mademan37 (< 20) Submitted: 2/14/2011 12:41:04 PM : Outperform Start Price: $10.14 ARAY Score: -83.97

Great company with a great product

Recs

0
Member Avatar guseter (< 20) Submitted: 11/4/2010 11:12:50 PM : Outperform Start Price: $6.85 ARAY Score: -63.68

Another unique-in-its-field company, also developing a constantly growing list of procedures for which Acuray's equipment will be the radiological treatment of choice, especially because its equipment automatically compensates for movements that take place during treatment of the targeted cancer site.

Recs

0
Member Avatar sallyparkinson (35.63) Submitted: 10/6/2010 5:12:37 AM : Outperform Start Price: $6.11 ARAY Score: -60.14

ARAY is a very innovative company and it is in a class by itself!!!The very fact that it is being very smrt and applying its technology in different directions show how clever it is..

Recs

0
Member Avatar pyupie0216 (< 20) Submitted: 8/18/2010 5:58:40 PM : Outperform Start Price: $6.93 ARAY Score: -85.19

screen

Recs

0
Member Avatar 21popsontop (< 20) Submitted: 6/27/2010 8:15:22 AM : Outperform Start Price: $6.92 ARAY Score: -87.13

This longshot has an interesting product in CyberKnife and with a global distributional and mutual back scratching hook up with Siemens AG deserves a hard look while in the pennies. I will add though,in a market like this you just might get it cheaper with Management looking to the lower end of guidance. Other than that Looks good post parade,and should at least bring those long odds in the trifecta to add value,good shot to get in the exacta,ha!ha!

Recs

0
Member Avatar lagunabb (22.15) Submitted: 6/3/2010 12:32:35 PM : Outperform Start Price: $6.02 ARAY Score: -68.23

200 systems installed is a big milestone and backlog is ramping faster than installations.

Recs

0
Member Avatar foolstracker (< 20) Submitted: 4/11/2010 5:35:46 PM : Outperform Start Price: $5.91 ARAY Score: -50.67

stock of the day

Recs

0
Member Avatar angliatzi (< 20) Submitted: 4/4/2010 11:10:20 AM : Outperform Start Price: $6.09 ARAY Score: -56.39

I believe that with the growing number of medically-insured people, the new regulations, and the need to be more cost-effective this stock will skyrocket. People will actually be able to afford these procedures because of their health insurance and their insurers cant deny them coverage, thus widening the poolof applicable candidates for this surgery.

Recs

3
Member Avatar pillip (< 20) Submitted: 4/1/2010 8:37:12 AM : Underperform Start Price: $6.07 ARAY Score: +56.67

Founder of company recently resigned from Board of Accuray and as a consultant to Accuray.to join Accuray's main competitor Varian citing poor management and business strategy at Accuray. Founder was also Accuray's largest individual shareholder.

Accuray being held back by reimbursement issuesin US for use of its only product, Cyberknife, and arrogant insular inexperienced management, Accuray lacks an effective strategy for addressing the critical reimbursemnt issue. Upper management poorly regarded internally and talented middle managers are leaving.

Stock is selling at one third of IPO price. Company has world class, game changing product but third world management. Company is doomed if current management is not replaced.

Recs

0
Member Avatar retired4037 (< 20) Submitted: 3/17/2010 7:13:08 PM : Underperform Start Price: $7.32 ARAY Score: +77.99

I have watched this stock sink over the past two years. Top management are the only ones that make out qtr after qtr. They treat the company like their own piggy bank. This is why the lawyers are circling

Recs

0
Member Avatar mizims (22.10) Submitted: 12/8/2009 2:45:29 AM : Underperform Start Price: $5.29 ARAY Score: +51.53

dog

Results 1 - 20 of 109 : 1 2 3 4 5 6 Next »

Featured Broker Partners


Advertisement